other material
confidence high
sentiment positive
materiality 0.75
4D Molecular reports positive 52-week Phase 2b data for wet AMD therapy 4D-150
4D Molecular Therapeutics, Inc.
- Phase 2b (n=30): 83% reduction in supplemental aflibercept injections (0.97 mean vs 6.0 on-label); 57% injection-free over 52 weeks.
- Recently diagnosed subgroup (n=15): 94% reduction (0.33 mean injections); 80% injection-free.
- Safety: well tolerated up to 3 years; 2.8% (2/71) 4D-150-related 1+ IOI; no hypotony, endophthalmitis, or vasculitis.
- Durable aflibercept expression up to 2 years; aqueous humor levels consistently within projected therapeutic range.
- Phase 3 trials 4FRONT-1 (Q1 2025) and 4FRONT-2 (Q3 2025) to initiate; topline 52-week data expected H2 2027.